Comparative Pharmacology
Head-to-head clinical analysis: BAYCOL versus LOVASTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAYCOL versus LOVASTATIN.
BAYCOL vs LOVASTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cerivastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing hepatic cholesterol production and increasing LDL receptor expression.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.
Cervastatin 0.4 mg orally once daily in the evening, with or without food.
10-80 mg orally once daily in the evening, starting at 10-20 mg once daily; maximum dose 80 mg/day.
None Documented
None Documented
2-4 hours (terminal elimination half-life); clinical context: supports twice-daily dosing
Clinical Note
moderateLovastatin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Norfloxacin
"The serum concentration of Norfloxacin can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Resveratrol
"The serum concentration of Resveratrol can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Betamethasone
Terminal elimination half-life: 1.5–2 hours for lovastatin acid; clinical context: short half-life supports evening dosing to maximize HMG-CoA reductase inhibition during peak cholesterol synthesis.
Renal: ~70% (mostly as unchanged drug); fecal: ~15%
Renal: 10% (as metabolites); Fecal: 83% (primarily as metabolites); Biliary: minor; <5% excreted unchanged in urine.
Category C
Category D/X
Statin
Statin
"The serum concentration of Betamethasone can be increased when it is combined with Lovastatin."